4SC AG expects to report data for its lead investigational compound, vidofludimus, in separate Phase 2 studies in inflammatory bowel disease and rheumatoid arthritis by the end of 2010. On 30 June, the German company had cash of €26.5 million. ---Subscribe to MedNous to access this article--- Company News
